Scientist I, Quantitative Systems Pharmacologist Revolution Medicines IncScientist I, Quantitative Systems PharmacologistRedwood City, CA$119,000–$149,000 / yearAs a Quantitative Systems Pharmacologist, you will: Develop, validate, execute, and refine quantitative systems pharmacology (QSP) models, minimal physiologically based pharmacokinetic (PBPK) models, semi-mechanistic PK/PD models, and tumor growth models to support development and discovery phase projects including next-generation inhibitor design and assessment of combination potential. This position will be responsible for developing, validating, and executing modeling projects with a focus on mechanistic PBPK-QSP mathematical models for small molecule programs to increase mechanistic understanding of compound PK behavior and drug distribution, pharmacological effects on RAS targets, support clinical translation, and drive future discovery and development efforts.
Scientist I, Quantitative Systems Pharmacologist Revolution MedicinesScientist I, Quantitative Systems PharmacologistRedwood City, CaliforniaAs a Quantitative Systems Pharmacologist, you will: Develop, validate, execute, and refine quantitative systems pharmacology (QSP) models, minimal physiologically based pharmacokinetic (PBPK) models, semi-mechanistic PK/PD models, and tumor growth models to support development and discovery phase projects including next-generation inhibitor design and assessment of combination potential. This position will be responsible for developing, validating, and executing modeling projects with a focus on mechanistic PBPK-QSP mathematical models for small molecule programs to increase mechanistic understanding of compound PK behavior and drug distribution, pharmacological effects on RAS targets, support clinical translation, and drive future discovery and development efforts.
NewSenior Director, Clinical Pharmacology Revolution Medicines IncSenior Director, Clinical PharmacologyRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Work with the Discovery organization to support assets in the IND-enabling stage, including collaboration with DMPK and Toxicology groups in assessment of human start dose and assessment of the need for human DDI studies.
NewSenior Director, Clinical Pharmacology Revolution MedicinesSenior Director, Clinical PharmacologyRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Work with the Discovery organization to support assets in the IND-enabling stage, including collaboration with DMPK and Toxicology groups in assessment of human start dose and assessment of the need for human DDI studies.
Computational Scientist II LancesoftComputational Scientist IISouth San Francisco, CA$45Prior exposure to LLM applications is a big plus whether through building and deploying LLM-powered pipelines, working with agentic frameworks such as LangSmith, retrieval-augmented generation (RAG) architectures, harness engineering or guardrail design, or integrating LLM APIs into functional tools. You will work at the interface of AI engineering and quantitative pharmacology, partnering closely with M&S Scientists and Clinical Pharmacologists to develop tools that are scientifically grounded, reliable, and impactful.
Vice President, Translational Research Revolution Medicines IncVice President, Translational ResearchRedwood City, CA$294,000–$367,000 / yearThe Opportunity: As a Vice President reporting to the SVP of Translational Research in Biology, the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines'' discovery and development portfolio. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Vice President, Translational Research Revolution MedicinesVice President, Translational ResearchRedwood City, CaliforniaAs a Vice President reporting to the SVP of Translational Research in Biology, the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines' discovery and development portfolio. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.